About IMUNON
IMUNON is a company based in Lawrenceville (United States) founded in 1982.. The company has 25 employees as of December 31, 2024. IMUNON offers products and services including DNA-based Therapies and Nucleic Acid Vaccines. IMUNON operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Lawrenceville, United States
- Employees 25 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Imunon, Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-18.62 M4.58as on Dec 31, 2024
-
EBITDA
$-18.41 M9.34as on Dec 31, 2024
-
Latest Funding Round
$3.25 M (USD), Post-IPO
May 23, 2025
- Investors
-
Employee Count
25
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of IMUNON
IMUNON is a publicly listed company on the NASDAQ with ticker symbol IMNN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of IMUNON
IMUNON offers a comprehensive portfolio of products and services, including DNA-based Therapies and Nucleic Acid Vaccines. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treats cancer using proprietary DNA platforms for immune enhancement.
Targets infectious diseases and cancer via DNA-based immune responses.
Funding Insights of IMUNON
- Total Funding Total Funding
- Total Rounds 10
- Last Round Post-IPO — $3.3M
-
First Round
First Round
(26 Jul 2010)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2025 | Amount | Post-IPO - IMUNON | Valuation |
investors |
|
| Aug, 2024 | Amount | Post-IPO - IMUNON | Valuation |
investors |
|
| Jun, 2015 | Amount | Post-IPO - IMUNON | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in IMUNON
IMUNON has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by IMUNON
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - IMUNON
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Imunon Comparisons
Competitors of IMUNON
IMUNON operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Imunon
Frequently Asked Questions about IMUNON
When was IMUNON founded?
IMUNON was founded in 1982 and raised its 1st funding round 28 years after it was founded.
Where is IMUNON located?
IMUNON is headquartered in Lawrenceville, United States.
Who is the current CEO of IMUNON?
Corinne Le Goff is the current CEO of IMUNON.
How many employees does IMUNON have?
As of Dec 31, 2024, the latest employee count at IMUNON is 25.
What does IMUNON do?
IMUNON was founded in 1982 and is based in Lawrenceville, United States, within the biotechnology sector. Focus is placed on developing immunotherapeutics for cancer, including the lead candidate GEN-1, a DNA-based immunotherapy targeted at ovarian cancer. The TheraPlas platform supports nucleic acid-based anti-cancer therapies, and the PLACCINE platform enables nucleic acid vaccines for infectious diseases and cancer applications. Operations emphasize research and development in these areas.
Who are the top competitors of IMUNON?
IMUNON's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
What products or services does IMUNON offer?
IMUNON offers DNA-based Therapies and Nucleic Acid Vaccines.
Is IMUNON publicly traded?
Yes, IMUNON is publicly traded on NASDAQ under the ticker symbol IMNN.
Who are IMUNON's investors?
IMUNON has 1 investor. Key investors include HHS.
What is IMUNON's ticker symbol?
The ticker symbol of IMUNON is IMNN on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.